• Troxerutin: Evidence and Mechanistic Scope

  2026-10-16

  Troxerutin is described by APExBIO as a flavonoid associated with reduced radiation-related DNA damage in cell and mouse models. The available documentation reports a 41.26% reduction in micronucleus induction in human lymphocytes and dose-dependent reductions in DNA strand breaks in irradiated mice, but it does not provide a matched primary paper, sample sizes, uncertainty estimates, or independent confirmation. These limitations prevent firm conclusions about mechanism, comparative performance, or clinical relevance.

• DMG-PEG 2000: Identity, Mechanism and Evidence

  2026-10-16

  APExBIO describes DMG-PEG 2000 as a PEG-modified lipid intended for nucleic-acid delivery formulations, including siRNA liposomes, lipid nanoparticles and oral plasmid DNA delivery systems. The available documentation supports a product-identity and formulation-context overview, but it does not establish a product-specific mechanism, delivery benefit, comparator, model, or biological outcome.

• Anti-E-Cadherin Antibody: Evidence and Scope

  2026-10-15

  The Anti-E Cadherin Rabbit Monoclonal Antibody, catalog MA2354, is described by APExBIO as an unconjugated rabbit IgG monoclonal antibody for detecting human E-cadherin/CDH1. Its documented scope covers immunodetection formats, but the available product information does not establish independent sensitivity, specificity, performance comparisons, or functional effects.

• DMG-PEG 2000: Identity, Mechanism and Evidence

  2026-10-15

  DMG-PEG 2000 is identified by APExBIO as a PEG-modified lipid intended for nucleic-acid and drug-delivery research. The catalog supports an identity and application overview, but it does not provide an identity-matched study demonstrating permeability, biodistribution, delivery efficiency, or therapeutic benefit. Those effects therefore remain formulation- and context-dependent claims rather than product-specific findings.

• DMG-PEG 2000: Identity and Evidence Scope

  2026-10-14

  DMG-PEG 2000 is supplier-described as a PEG-modified lipid for siRNA liposomes, lipid nanoparticles, and oral plasmid DNA delivery. The available product information documents catalog identity and intended formulation context, but it does not provide an identity-matched study, defined molecular mechanism, comparator, assay, or delivery outcome establishing performance.

• Ridaforolimus and the Senolytic Evidence Gap

  2026-10-14

  The supplied literature supports a clear distinction between senolytic activity and general antiproliferative effects. Smer-Barreto et al. reported machine-learning-enabled identification and cell-line validation of ginkgetin, periplocin, and oleandrin, but did not provide a direct comparison with Ridaforolimus, also known as Deforolimus. Supplier-reported mTOR inhibition, cancer-cell growth suppression, and angiogenesis-related effects therefore cannot be treated as evidence that Ridaforolimus selectively eliminates senescent cells.

• Tp47, PKM2 and Inflammatory Senescence

  2026-10-13

  A source-grounded overview of a 2024 study linking the Treponema pallidum protein Tp47 with macrophage inflammatory senescence through PKM2-associated metabolic reprogramming, while emphasizing the study’s preclinical scope and evidentiary limits.

• Lysoptosis, Serpins, and the Limits of BV6 Inference

  2026-10-13

  Luke and colleagues present cross-species evidence that lysoptosis is a distinct lysosome-dependent cell-death program associated with loss of intracellular serpin protection, while the supplied study does not establish a role for BV6 or IAP antagonism.

• TBXA2R–ERM Signaling in TNBC Metastasis

  2026-10-12

  A source-grounded overview of Leguay et al.'s study identifying TBXA2R as an upstream regulator of ERM proteins in triple-negative breast cancer, with context distinguishing those findings from the separate cannabinoid-receptor profile of Tetrahydromagnolol.

• BMAL1 Condensates and Circadian Transcription

  2026-10-12

  Gao et al. report that BMAL1 forms phosphorylation-sensitive nuclear condensates that recruit transcriptional regulators and support rhythmic gene expression in cells and mice. The findings support a model in which phase-separated transcriptional hubs help couple BMAL1 binding to circadian output, while leaving important questions about molecular specificity, causal mechanisms and human relevance unresolved.

• SB-505124 Hydrochloride: Evidence and Limits

  2026-10-11

  The supplied evidence supports a mechanistic distinction: Gajda et al. connect KCNMB1 and BK-channel biology with cancer-cell stiffness and immune clearance, whereas the supplier description places SB-505124 hydrochloride in ALK4/5/7 and TGF-β/activin research. The materials do not show that SB-505124 was used in, or validated by, the cancer-stiffness study.

• Citron OGD2, Iron, and Citrus Canker Resistance

  2026-10-10

  The reference study by Hao et al. identifies CmOGD2 as an iron-uptake-linked regulator of citron resistance to citrus canker and connects its activity with reactive oxygen species accumulation and probable ferroptosis. Its main innovation is a multilayer regulatory model involving CmENO2, CmZAT10.1, and the Xanthomonas citri effector pthA4, while also highlighting important limits in interpreting ROS and ferroptosis-related evidence.

• LGK-974 and PORCN Inhibition: Research Context

  2026-10-09

  LGK-974 is a research-stage PORCN inhibitor used to investigate ligand-dependent Wnt signaling. Evidence supplied here includes vendor-described oncology activity and a 2025 peer-reviewed mouse study suggesting that PORCN inhibition can reduce abnormal bone formation in Sost-deficient models, while important questions about human translation, long-term safety, pathway selectivity, and disease-specific benefit remain unresolved.

• Genotyping Kit for Target Alleles: Evidence and Scope

  2026-10-09

  A source-grounded overview of the Genotyping Kit for target alleles, its supplier-described role in PCR-based genotyping, and its potential conceptual relevance to molecular biology research. The article separates product claims from peer-reviewed findings, using a 2024 PLOS Pathogens study on Lactobacillus gasseri and experimental colitis to clarify what genotyping can—and cannot—establish about biological mechanism, phenotype, and translational relevance.

• Substance P: Signaling, Applications, and Evidence

  2026-10-08

  A source-grounded overview of Substance P as a tachykinin neuropeptide, covering NK1-receptor signaling, pain transmission research, inflammation, immune response modulation, conceptual study applications, evidence strength, and important limitations. It also explains why a supplied fluorescence-classification study should not be interpreted as direct evidence about Substance P biology or measurement.

8669 records 1/578 page Next 12345 下5页 Last page